Elutia (ELUT) Competitors $2.10 -0.06 (-2.55%) Closing price 07/3/2025 01:56 PM EasternExtended Trading$2.09 -0.02 (-0.71%) As of 07/3/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. TKNO, RCKT, AVTE, GLUE, PRME, OLMA, AVIR, ADCT, TRDA, and CRVSShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), Aerovate Therapeutics (AVTE), Monte Rosa Therapeutics (GLUE), Prime Medicine (PRME), Olema Pharmaceuticals (OLMA), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Entrada Therapeutics (TRDA), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors Alpha Teknova Rocket Pharmaceuticals Aerovate Therapeutics Monte Rosa Therapeutics Prime Medicine Olema Pharmaceuticals Atea Pharmaceuticals ADC Therapeutics Entrada Therapeutics Corvus Pharmaceuticals Alpha Teknova (NASDAQ:TKNO) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Which has stronger valuation & earnings, TKNO or ELUT? Alpha Teknova has higher revenue and earnings than Elutia. Alpha Teknova is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlpha Teknova$38.25M7.29-$26.75M-$0.48-10.88Elutia$24.38M3.55-$53.95M-$1.93-1.09 Which has more volatility & risk, TKNO or ELUT? Alpha Teknova has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Is TKNO or ELUT more profitable? Alpha Teknova has a net margin of -60.90% compared to Elutia's net margin of -168.23%. Elutia's return on equity of 0.00% beat Alpha Teknova's return on equity.Company Net Margins Return on Equity Return on Assets Alpha Teknova-60.90% -28.48% -19.73% Elutia -168.23%N/A -96.70% Do analysts recommend TKNO or ELUT? Alpha Teknova currently has a consensus price target of $8.50, indicating a potential upside of 62.84%. Elutia has a consensus price target of $8.00, indicating a potential upside of 280.05%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Alpha Teknova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TKNO or ELUT? In the previous week, Alpha Teknova had 2 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Alpha Teknova and 2 mentions for Elutia. Elutia's average media sentiment score of 0.77 beat Alpha Teknova's score of 0.63 indicating that Elutia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Teknova 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in TKNO or ELUT? 13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 12.5% of Alpha Teknova shares are owned by company insiders. Comparatively, 27.6% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryAlpha Teknova and Elutia tied by winning 7 of the 14 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.56M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.10%P/E Ratio-1.0921.5627.4720.28Price / Sales3.55244.81408.86121.46Price / CashN/A41.9536.6357.47Price / Book-1.617.518.095.68Net Income-$53.95M-$55.05M$3.17B$248.96M7 Day Performance0.24%4.61%2.81%3.30%1 Month Performance9.64%4.89%3.67%5.20%1 Year Performance-51.94%5.84%35.41%21.37% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.9178 of 5 stars$2.11-2.5%$8.00+280.0%-51.8%$86.56M$24.38M-1.09180Gap DownTKNOAlpha Teknova3.0694 of 5 stars$5.28-5.0%$8.50+61.0%+331.4%$297.13M$37.74M-11.00240RCKTRocket Pharmaceuticals4.8883 of 5 stars$2.63-2.6%$18.60+607.2%-85.5%$288.32MN/A-1.00240Trending NewsAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-81.7%$286.66MN/A-3.3120High Trading VolumeGLUEMonte Rosa Therapeutics1.1962 of 5 stars$4.64+0.2%$15.50+234.1%+29.7%$284.79M$75.62M58.0190News CoveragePRMEPrime Medicine3.5886 of 5 stars$2.16+4.3%$10.08+366.8%-40.8%$283.60M$3.85M-1.05234Gap UpHigh Trading VolumeOLMAOlema Pharmaceuticals1.7743 of 5 stars$4.19+1.5%$24.50+484.7%-58.8%$282.58MN/A-2.0870AVIRAtea Pharmaceuticals2.3965 of 5 stars$3.32+2.2%$6.00+80.7%+11.9%$278.13MN/A-2.0170ADCTADC Therapeutics1.7319 of 5 stars$2.68-3.2%$7.75+189.2%-8.8%$274.72M$70.84M-1.85310TRDAEntrada Therapeutics3.394 of 5 stars$7.04-1.1%$25.67+264.6%-49.0%$270.23M$210.78M8.69110Insider TradeCRVSCorvus Pharmaceuticals2.5217 of 5 stars$3.73-5.8%$15.00+302.1%+121.1%$269.95MN/A-3.8130Insider Trade Related Companies and Tools Related Companies TKNO Competitors RCKT Competitors AVTE Competitors GLUE Competitors PRME Competitors OLMA Competitors AVIR Competitors ADCT Competitors TRDA Competitors CRVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELUT Stock Alerts